Mission

ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value.  Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.

Staff Only

Remember Me
TwitterLinkedinFacebookFeed
Reviews of the Comparative Clinical Effectiveness and/or Comparative Value of Pharmaceuticals

Canadian Agencies for Drugs and Technologies in Health (CADTH)

Common Drug Review Database

The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec).

http://cadth.ca/index.php/en/cdr/search

The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS)

COMPUS identifies and promotes optimal drug therapy and encourages the use of evidence-based clinical and cost-effectiveness information among health care providers and consumers.

 http://www.cadth.ca/en/products/therapeutic-reviews

Medical Services Advisory Committee, Australian government (MSAC)

Pharmaceutical Benefits Advisory Committee (PBAC)
The PBAC is an independent statutory body that advises the Australian government on drugs and medications that should be made available as pharmaceutical benefits.
http://www.health.gov.au/internet/main/publishing.nsf/Content/public-summary-documents

 Oregon Health & Science University (OHSU) Drug Effectiveness Review Project (DERP)

DERP is a self-governing collaboration of public and private organizations that provides systematic reviews of the comparative effectiveness and safety of drugs in order to inform public policy and related activities in local settings.
http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy-center/derp/index.cfm/?WT_rank=1